Edgewise Therapeutics to Present at Leerink Conference on March 11, 2026
Event summary
- Edgewise Therapeutics will present at the Leerink Global Healthcare Conference on March 11, 2026, at 1:40 p.m. ET.
- The presentation will be webcast live and available for replay for a limited time.
- Edgewise is developing Sevasemten for muscular dystrophies, EDG-7500 for hypertrophic cardiomyopathy, and EDG-15400 for heart failure.
- Behrad Derakhshan, Ph.D., Chief Operating Officer, and Maureen Franco, VP Corporate Communications, are the designated contacts for investors and media, respectively.
The big picture
Edgewise Therapeutics is positioning itself as a key player in the muscle disease biopharmaceutical space, with a focus on novel therapeutics for muscular dystrophies and cardiac conditions. The upcoming presentation at the Leerink Global Healthcare Conference is a strategic opportunity to showcase its pipeline progress and attract investor attention. The company's deep expertise in muscle physiology and its diverse pipeline could drive significant market impact if clinical trials continue to show promising results.
What we're watching
- Clinical Progress
- How the late-stage trials of Sevasemten for muscular dystrophies will impact Edgewise's market positioning.
- Pipeline Development
- Whether EDG-7500 and EDG-15400 can advance through their respective clinical phases to bolster Edgewise's portfolio.
- Investor Sentiment
- The pace at which investor confidence will be influenced by the company's presentation and upcoming clinical data.
Related topics